Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

A phase 2 trial of ixabepilone plus cetuximab in first-line treatment of metastatic pancreatic cancer.

Rocha Lima CM, Lin EH, Kim GP, Giguere JK, Marshall J, Zalupski M, Papageorgio C, Auber ML, Kaleta R, McHenry MB, Trifan OC, Philip PA.

Gastrointest Cancer Res. 2012 Sep;5(5):155-60.

2.

Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.

Steinberg M.

Clin Ther. 2008 Sep;30(9):1590-617. doi: 10.1016/j.clinthera.2008.09.015. Review.

PMID:
18840366
3.

Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer.

Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA.

Cancer. 2008 Oct 15;113(8):2046-52. doi: 10.1002/cncr.23810.

4.

Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer.

Wang F, Wang Z, Zhou N, An X, Xu R, He Y, Li Y.

Am J Clin Oncol. 2011 Aug;34(4):401-5. doi: 10.1097/COC.0b013e3181e84b63.

PMID:
21791984
5.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
6.

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.

Thomas E, Tabernero J, Fornier M, Conté P, Fumoleau P, Lluch A, Vahdat LT, Bunnell CA, Burris HA, Viens P, Baselga J, Rivera E, Guarneri V, Poulart V, Klimovsky J, Lebwohl D, Martin M.

J Clin Oncol. 2007 Aug 10;25(23):3399-406. Epub 2007 Jul 2.

PMID:
17606975
7.

A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study.

Whitehead RP, McCoy S, Rivkin SE, Gross HM, Conrad ME, Doolittle GC, Wolff RA, Goodwin JW, Dakhil SR, Abbruzzese JL.

Invest New Drugs. 2006 Nov;24(6):515-20.

PMID:
16699973
8.

A Phase II Multi-Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma.

Burotto M, Edgerly M, Velarde M, Balasubramaniam S, Drabkin H, Gormaz JG, O'Sullivan C, Madan R, Fojo T.

Oncologist. 2017 Aug;22(8):888-e84. doi: 10.1634/theoncologist.2017-0211. Epub 2017 Jul 5.

9.

Phase II Trial of Cetuximab and Conformal Radiotherapy Only in Locally Advanced Pancreatic Cancer with Concurrent Tissue Sampling Feasibility Study.

Rembielak AI, Jain P, Jackson AS, Green MM, Santorelli GR, Whitfield GA, Crellin A, Garcia-Alonso A, Radhakrishna G, Cullen J, Taylor MB, Swindell R, West CM, Valle J, Saleem A, Price PM.

Transl Oncol. 2014 Feb 1;7(1):55-64. eCollection 2014 Feb.

10.

A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.

Montero AJ, Kwon D, Flores A, Kovacs K, Trent JC, Benedetto P, Rocha-Lima C, Merchan JR.

Clin Cancer Res. 2016 Jul 1;22(13):3209-17. doi: 10.1158/1078-0432.CCR-15-2184. Epub 2016 Feb 10.

11.

Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.

Van Laethem JL, Riess H, Jassem J, Haas M, Martens UM, Weekes C, Peeters M, Ross P, Bridgewater J, Melichar B, Cascinu S, Saramak P, Michl P, Van Brummelen D, Zaniboni A, Schmiegel W, Dueland S, Giurescu M, Garosi VL, Roth K, Schulz A, Seidel H, Rajagopalan P, Teufel M, Childs BH.

Target Oncol. 2017 Feb;12(1):97-109. doi: 10.1007/s11523-016-0469-y.

PMID:
27975152

Supplemental Content

Support Center